We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Day Two: Oncology Panel Votes Again in Favor of Maintaining Accelerated Approvals for Cancer Drugs
Day Two: Oncology Panel Votes Again in Favor of Maintaining Accelerated Approvals for Cancer Drugs
The FDA’s Oncologic Drugs Advisory Committee met Wednesday for its day two discussion of accelerated approvals for PD-1/L1 inhibitors that haven’t verified their benefit in confirmatory trials, recommending the agency hold off on withdrawing bladder cancer indications for Merck’s Keytruda (pembrolizumab) and Roche’s Tecentriq (atezolizumab).